Skip to main content

Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement

  • Chapter

Part of the Medical Science Symposia Series book series (MSSS,volume 11)

Abstract

Estrogen replacement in pre- and postmenopausal women provides an effective relief of typical climacteric complaints. However, the addition of a progestogen is essential to reduce the risk of endometrial cancer and to control cycle irregularities in the perimenopausal period. In postmenopausal women the androgen formation is almost unchanged and responsible for lowering HDL concentrations on the one hand and is involved in the development of insulin resistance on the other. Thus, it is expected that the combination of estradiol valerate (E2V) with cyproterone acetate (CPA), a progestogen with strong antiandrogenic effects, will augment the beneficial effects of estradiol on lipid and carbohydrate metabolism. For this reason climen was developed and is now available in 41 countries all over the world. It is a preparation with 21 days of 2 mg E2V and a 10-day addition of 1 mg CPA. This regimen is followed by a treatment-free 7-day interval. In a randomized, double-blind, multicenter study, 594 patients were treated for 12 months: 293 patients with climen and the remaining 301 patients, as control, were given a combination of 2 mg estradiol valerate for 21 days plus 0.5 mg norgestrel for 10 days.

Keywords

  • Postmenopausal Woman
  • Endometrial Cancer
  • Cyproterone Acetate
  • Postmenopausal Bone Loss
  • Estradiol Valerate

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-94-011-5560-1_38
  • Chapter length: 5 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   59.99
Price excludes VAT (USA)
  • ISBN: 978-94-011-5560-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   79.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schneider HPG, Schmidt-Gollwitzer K. Clinical experiences with a non-androgenic progestogen in an estradiol-valerate-containing regimen for hormone replacement therapy. In: Schneider HPG, Schmidt-Gollwitzer K, editors. A new approach in the treatment of climacteric disorders. New developments of biosciences 7. Berlin: Walter de Gruyter, 1992: 17–28.

    Google Scholar 

  2. Husmann F. Schlafstörungen. In: Climacterium feminale. 2nd edition. Leonberg, Germany: Kurt Pamminger, 1996: 61–66.

    Google Scholar 

  3. Genazzani AR, Petraglia F, Mercuri N, Genazzani AD, Sgherzi MR, Aguzzoli L, Volpogni C. Cyproterone acetate as progestin in the treatment of climacteric women. In: Schneider HPG, Schmidt-Gollwitzer K, editors. A new approach in the treatment of climacteric disorders. New developments of biosciences 7. Berlin: Walter de Gruyter, 1992: 29–36.

    Google Scholar 

  4. Bachmann GA. Vulvovaginal complaints. In: Lobo RA, editor. Treatment of the postmenopausal women. Basic and clinical aspects. New York: Raven Press, 1994: 137–42.

    Google Scholar 

  5. Tikkanen MJ. Combination of estradiol-valerate and cyproterone acetate — a modern regimen for hormone replacement therapy. In: Schneider HPG, Schmidt-Gollwitzer K, editors. A new approach in the treatment of climacteric disorders. New developments of biosciences 7. Berlin: Walter de Gruyter, 1992: 9–15.

    Google Scholar 

  6. Christiansen C. Cyproterone acetate in hormone replacement therapy. In: Schneider HPG, Schmidt-Gollwitzer K, editors. A new approach in the treatment of climacteric disorders. New developments of biosciences 7. Berlin: Walter de Gruyter, 1992: 1–8.

    Google Scholar 

  7. Koninckx PR, Lauweryns JA, Cornille FJ. The effects of a sequential estradiol-valerate cyproterone acetate preparation on the endometrium during hormone replacement therapy. In: Schneider HPG, Schmidt-Gollwitzer K, editors. A new approach in the treatment of climacteric disorders. New developments of biosciences 7. Berlin: Walter de Gruyter, 1992: 37–53.

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Husmann, F. (1997). Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement. In: Paoletti, R., Crosignani, P.G., Kenemans, P., Samsioe, G., Soma, M.R., Jackson, A.S. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5560-1_38

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5560-1_38

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6343-2

  • Online ISBN: 978-94-011-5560-1

  • eBook Packages: Springer Book Archive